文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛儿科与产科急症

Covid-19疫苗在门诊和住院医疗环境中的有效性

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
PubMed 文献 · N Engl J Med · 2021-09-08
一句话结论在美国≥50岁成人中,全程mRNA疫苗接种对需住院、ICU入住或急诊/紧急护理就诊的SARS-CoV-2感染有效性为89%-91%,Ad26.COV2.S疫苗为68%-73%。

该研究采用检测阴性设计,纳入2021年1月1日至6月22日多州187家医院41,552例住院和221家急诊/紧急护理机构21,522例就诊的≥50岁Covid-19样疾病成人,通过电子健康记录和免疫登记确定接种状态。全程mRNA疫苗接种(第二剂后≥14天)对实验室确诊SARS-CoV-2感染导致住院的有效性为89%(95%CI 87-91),导致ICU入住为90%(95%CI 86-93),导致急诊/紧急护理就诊为91%(95%CI 89-93)。Ad26.COV2.S疫苗对住院和急诊/紧急护理就诊的有效性分别为68%(95%CI 50-79)和73%(95%CI 59-82)。全程mRNA疫苗对住院或急诊/紧急护理就诊的有效性在85岁及以上、慢性病患者及黑人或西班牙裔成人中为81%-95%。

要点

  • 全程mRNA疫苗接种(第二剂后≥14天)对≥50岁成人SARS-CoV-2感染导致住院的有效性为89%(95%CI 87-91)。
  • 全程mRNA疫苗接种对SARS-CoV-2感染导致ICU入住的有效性为90%(95%CI 86-93)。
  • 全程mRNA疫苗接种对SARS-CoV-2感染导致急诊或紧急护理就诊的有效性为91%(95%CI 89-93)。
  • Ad26.COV2.S疫苗对住院和急诊/紧急护理就诊的有效性分别为68%(95%CI 50-79)和73%(95%CI 59-82)。
  • 全程mRNA疫苗对住院或急诊/紧急护理就诊的有效性在≥85岁、慢性病患者及黑人或西班牙裔成人中为81%-95%。

适用人群与场景

  • ≥50岁成人,具有Covid-19样疾病并接受SARS-CoV-2分子检测者。
  • 场景包括住院(187家医院)和急诊或紧急护理就诊(221家机构),多州,2021年1月1日至6月22日。

诊断标准与关键阈值

  • 全程mRNA疫苗接种定义为第二剂后≥14天。
  • 采用检测阴性设计,比较接种与未接种患者SARS-CoV-2检测阳性的比值。
  • 疫苗有效性经倾向性评分权重调整,并调整年龄、地理区域、日历时间(2021年1月1日至每次就诊索引日期的天数)和局部病毒流行。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:检测阴性设计研究;样本量:住院41,552例(187家医院)和急诊/紧急护理就诊21,522例(221家机构);人群:≥50岁Covid-19样疾病成人;多州,2021年1月1日至6月22日。
  • 全程mRNA疫苗接种对实验室确诊SARS-CoV-2感染导致住院的有效性为89%(95%CI 87-91),导致ICU入住为90%(95%CI 86-93),导致急诊/紧急护理就诊为91%(95%CI 89-93)。
  • 全程mRNA疫苗对住院或急诊/紧急护理就诊的有效性在BNT162b2和mRNA-1273疫苗间相似,在≥85岁、慢性病患者及黑人或西班牙裔成人中范围为81%-95%。
  • Ad26.COV2.S疫苗对住院的有效性为68%(95%CI 50-79),对急诊/紧急护理就诊为73%(95%CI 59-82)。

证据类型、等级与局限

  • 证据类型:观察性检测阴性设计研究;局限:原文未明确列出,但设计本身为观察性、非随机化。

对床旁实践的改变

  • 支持≥50岁成人全程接种mRNA疫苗以预防需住院、ICU入住或急诊/紧急护理就诊的SARS-CoV-2感染;Ad26.COV2.S疫苗同样有效但有效性数值较低。

指南或共识出处

  • 原文未提及指南或共识名称;研究由美国疾病控制与预防中心资助。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect to hospitalization, admission to an intensive care unit (ICU), or ambulatory care in an emergency department or urgent care clinic.

METHODS: We conducted a study involving adults (≥50 years of age) with Covid-19-like illness who underwent molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed 41,552 admissions to 187 hospitals and 21,522 visits to 221 emergency departments or urgent care clinics during the period from January 1 through June 22, 2021, in multiple states. The patients' vaccination status was documented in electronic health records and immunization registries. We used a test-negative design to estimate vaccine effectiveness by comparing the odds of a positive test for SARS-CoV-2 infection among vaccinated patients with those among unvaccinated patients. Vaccine effectiveness was adjusted with weights based on propensity-for-vaccination scores and according to age, geographic region, calendar time (days from January 1, 2021, to the index date for each medical visit), and local virus circulation.

RESULTS: The effectiveness of full messenger RNA (mRNA) vaccination (≥14 days after the second dose) was 89% (95% confidence interval [CI], 87 to 91) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization, 90% (95% CI, 86 to 93) against infection leading to an ICU admission, and 91% (95% CI, 89 to 93) against infection leading to an emergency department or urgent care clinic visit. The effectiveness of full vaccination with respect to a Covid-19-associated hospitalization or emergency department or urgent care clinic visit was similar with the BNT162b2 and mRNA-1273 vaccines and ranged from 81% to 95% among adults 85 years of age or older, persons with chronic medical conditions, and Black or Hispanic adults. The effectiveness of the Ad26.COV2.S vaccine was 68% (95% CI, 50 to 79) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization and 73% (95% CI, 59 to 82) against infection leading to an emergency department or urgent care clinic visit.

CONCLUSIONS: Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit. This vaccine effectiveness extended to populations that are disproportionately affected by SARS-CoV-2 infection. (Funded by the Centers for Disease Control and Prevention.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021. PMID: 34496194. doi:10.1056/NEJMoa2110362

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。